Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Trial Details

NCT ID

NCT07689175

Phase

PHASE2

Sponsor

University of Texas Southwestern Medical Center

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

• Nivolumab
• Ipilimumab (3 mg/kg)

Locations (sample)

• Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

• Patient must have a diagnosis confirmed by histology or clinically by the American Association for the Study of Liver Diseases (AASLD) criteria in …
• Patients may not have received any prior anti-PD-1/L1 or anti-CTLA-4 therapies for the treatment of advanced HCC.
• Patients with locally advanced or metastatic disease must have disease deemed not amenable to surgical and/or locoregional therapies or patients wh…
• Child-Pugh Score B7-8

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.